Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | Baker Bros. Advisors LP | 56,482 8.000% | 4,145 (+7.92%) | Filing History |
| 2023-02-14 3:10 pm Purchase | 2022-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | Cormorant Asset Management LP | 55,918 7.950% | 3,613 (+6.91%) | Filing History |
| 2023-02-14 08:02 am Sale | 2022-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | Citadel Advisors LLC | 44,628 6.400% | -1,014 (-2.22%) | Filing History |
| 2023-02-03 7:24 pm Purchase | 2022-11-14 | 13D | Aerovate Therapeutics, Inc. AVTE | Sofinnova Venture Partners X L.P. | 108,104 15.400% | 673 (+0.63%) | Filing History |
| 2022-12-15 4:06 pm Sale | 2022-12-12 | 13D | Aerovate Therapeutics, Inc. AVTE | Atlas Venture Fund XII, L.P. | 58,264 8.300% | -8,691 (-12.98%) | Filing History |
| 2022-07-20 4:22 pm Sale | 2022-07-15 | 13D | Aerovate Therapeutics, Inc. AVTE | Atlas Venture Fund XII, L.P. | 66,955 9.600% | -8,691 (-11.49%) | Filing History |
| 2022-05-05 4:04 pm Purchase | 2022-04-01 | 13D | Aerovate Therapeutics, Inc. AVTE | Atlas Venture Fund XII, L.P. | 75,646 10.800% | 75,646 (New Position) | Filing History |
| 2022-02-14 4:14 pm Purchase | 2021-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | Baker Bros. Advisors LP | 52,337 7.500% | 52,337 (New Position) | Filing History |
| 2022-02-14 3:10 pm Sale | 2021-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | Cormorant Asset Management LP | 52,305 7.500% | -5,714 (-9.85%) | Filing History |
| 2022-02-14 06:22 am Sale | 2021-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | Citadel Advisors LLC | 45,642 6.500% | -791 (-1.70%) | Filing History |
| 2021-11-05 4:38 pm Purchase | 2021-07-02 | 13D | Aerovate Therapeutics, Inc. AVTE | Atlas Venture Associates XII LLC | 88,682 12.700% | 88,682 (New Position) | Filing History |
| 2021-07-13 1:49 pm Purchase | 2021-07-02 | 13D | Aerovate Therapeutics, Inc. AVTE | Sofinnova Venture Partners X L.P. | 107,431 16.300% | 107,431 (New Position) | Filing History |
| 2021-07-12 5:13 pm Purchase | 2021-07-02 | 13D | Aerovate Therapeutics, Inc. AVTE | RA Capital Management, L.P. | 236,114 33.900% | 236,114 (New Position) | Filing History |
| 2021-07-12 4:19 pm Purchase | 2021-07-02 | 13G | Aerovate Therapeutics, Inc. AVTE | Cormorant Asset Management LP | 58,020 8.320% | 58,020 (New Position) | Filing History |
| 2021-07-12 4:03 pm Purchase | 2021-07-02 | 13G | Aerovate Therapeutics, Inc. AVTE | Citadel Advisors LLC | 46,434 6.700% | 46,434 (New Position) | Filing History |